

— *Journal of the American Medical Association*, 1997

5 The method comprises administering to patients in need thereof therapeutically effective amounts of a TNF binding protein and methotrexate (N-[4-[[2,4-diamino-6-pteridiny]methylamino]benzoyl]-L-glutamic acid). In a preferred embodiment, the TNF binding protein is
0 sTNFR-I or sTNFR-II. The invention also relates to pharmaceutical compositions containing a TNF binding protein and methotrexate useful in such methods.